CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market
New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve
- Live webcast on Wednesday, June 24th at 2:00 PM ET
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve
Company ended the first quarter with approximately $25 million in cash and investments
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial
Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed
IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse...